Does osimertinib treatment discriminate young patients?

Affiliations

¹ Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
² Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine of Geriatric Diseases, Medical College of Soochow University, Suzhou 215123, China.
³ Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Center, Atlanta, GA, USA.

Editorial

Cheng Ji et al. J Thorac Dis. 2019 Sep.

. 2019 Sep;11(Suppl 15):S1852-S1854.

doi: 10.21037/jtd.2019.08.118.

¹ Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
² Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine of Geriatric Diseases, Medical College of Soochow University, Suzhou 215123, China.
³ Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Center, Atlanta, GA, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
Kato Y, Hosomi Y, Watanabe K, Yomota M, Kawai S, Okuma Y, Kubota K, Seike M, Gemma A, Okamura T. Kato Y, et al. J Thorac Dis. 2019 Jun;11(6):2350-2360. doi: 10.21037/jtd.2019.06.03. J Thorac Dis. 2019. PMID: 31372272 Free PMC article.

1. Govindan R. Overcoming resistance to targeted therapy for lung cancer. N Engl J Med 2015;372:1760-1. 10.1056/NEJMe1500181 - DOI - PubMed
1. Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2018;36:841-9. 10.1200/JCO.2017.74.7576 - DOI - PubMed
1. Liu M, Cai X, Yu W, et al. Clinical significance of age at diagnosis among young non-small cell lung cancer patients under 40 years old: a population-based study. Oncotarget 2015;6:44963-70. 10.18632/oncotarget.5524 - DOI - PMC - PubMed
1. Liu B, Quan X, Xu C, et al. Lung cancer in young adults aged 35 years or younger: A full-scale analysis and review. J Cancer 2019;10:3553-9. 10.7150/jca.27490 - DOI - PMC - PubMed
1. Goto K, Nishio M, Yamamoto N, et al. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer 2013;82:109-14. 10.1016/j.lungcan.2013.07.003 - DOI - PubMed